JersildCSvejgaardAFogT.HL-A antigens and multiple sclerosis. Lancet1972; 1(7762): 1240–1241.
2.
MoutsianasLJostinsLBeechamAH, et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat Genet2015; 47(10): 1107–1113.
3.
GoodinDSKhankhanianPGourraudPA, et al. Genetic susceptibility to multiple sclerosis: Interactions between conserved extended haplotypes of the MHC and other susceptibility regions. BMC Med Genomics2021; 14(1): 183.
4.
International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, SawcerS, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476(7359): 214–219.
5.
GeorgeMFBriggsFBShaoX, et al. Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurol Genet2016; 2(4): e87.
6.
JacksonKCSunKBarbourC, et al. Genetic model of MS severity predicts future accumulation of disability. Ann Hum Genet2020; 84(1): 1–10.
7.
JokubaitisVGIbrahimOStankovichJ, et al. Not all roads lead to the immune system: The genetic basis of multiple sclerosis severity implicates central nervous system and mitochondrial involvement. Medrxiv [preprint] 2022. DOI: /10.1101/2022.02.04.22270362.
8.
MastermanTLigersAOlssonT, et al. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol2000; 48(2): 211–219.
9.
BrownleeW.HLA-DRB1*1501 influences long term disability progression and tissue damage on MRI in relapse-onset multiple sclerosis. Mult Scler J2022; 13524585221130941. DOI: 10.1177/13524585221130941.
10.
OkudaDTSrinivasanROksenbergJR, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain2009; 132(Pt. 1): 250–259.
11.
IsobeNKeshavanAGourraudPA, et al. Association of HLA genetic risk burden with disease phenotypes in multiple sclerosis. JAMA Neurol2016; 73(7): 795–802.
12.
TintoreMCobo-CalvoACarbonellP, et al. Effect of changes in MS diagnostic criteria over 25 years on time to treatment and prognosis in patients with clinically isolated syndrome. Neurology2021; 97: e1641–e1652.
13.
JokubaitisVGSpelmanTKalincikT, et al. Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol2015; 2(5): 479–491.
14.
KavaliunasAManouchehriniaAStawiarzL, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler2017; 23(9): 1233–1240.
15.
LapucciCSchiaviSSignoriA, et al. The role of disconnection in explaining disability in multiple sclerosis. Eur Radiol Exp2022; 6(1): 23.
